基本信息
浏览量:15
职业迁徙
个人简介
Prof. Parren is dedicated to translate antibody biology and immunotherapy knowledge into innovative therapeutics and technologies. He has a passion for investigating and understanding structure-function relationships and translating the knowledge gained into immunotherapy applications and drug development. He is an inventor of the therapeutic antibodies ofatumumab (Arzerra, Kesimpta) daratumumab (DARZALEX), teprotumumab (Tepezza), tisotumab vedotin (Tivdak) en amivantamab (Rybrevant). Ofatumumab was approved in 2009 for the treatment of Chronic Lymphocytic Leukemia and in 2020 in a subcutaneous formulation for Multiple Sclerosis. Ofatumumab received the Dutch Galenus Prize in 2011 for most innovative new medicine. Ofatumumab (Arzerra) has, for the treatment of cancer, since been transitioned to compassionate use and oncology access programs. Daratumumab was first approved in 2015 for the treatment of Multiple Myeloma. Teprotumumab was approved for the treatment of Active Thyroid Eye Disease (Graves’ orbitopathy in 2020. Tisotumab vedotin (an antibody-drug conjugate) and amivantamab (an EGFR-cMet bispecific antibody) were approved in 2021 by FDA for the treatment of recurrent or metastatic cervical cancer and for metastatic NSCLC with EGFR exon 20 insertion, respectively. Paul Parren further invented and developed several clinically translated technologies aimed at improving antibody therapy, including bispecific antibodies and effector function-enhanced antibodies (DuoBody and HexaBody platforms). The first bispecific antibody product based on the DuoBody technology obtained regulatory approval in 2021. His work has thus far directly led to four therapeutic antibodies that received FDA Breakthrough Therapy designation and ten further therapeutic antibodies in various formats currently in clinical development for the treatment of cancer and Parkinson’s disease.
研究兴趣
论文共 479 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Frontiers in immunology (2024): 1288597-1288597
crossref(2023)
crossref(2023)
Cancer gene therapyno. 1 (2023): 58-68
Michael J. Flynn,Francesca Zammarchi,Peter C. Tyrer,Ayse U. Akarca,Narinder Janghra,Charles E. Britten,Carin E.G. Havenith,Jean-Noel Levy,Arnaud Tiberghien,Luke A. Masterson,Conor Barry,Francois D'Hooge,Teresa Marafioti,Paul W.H.I. Parren,David G. Williams,Philip W. Howard,Patrick H. van Berkel,John A. Hartley
crossref(2023)
FRONTIERS IN IMMUNOLOGY (2023)
Marije B. Overdijk, Kristin Strumane, Frank J. Beurskens, Antonio Ortiz Buijsse, Claudine Vermot-Desroches, Boris S. Vuillermoz, Thessa Kroes, Bart de Jong,Naomi Hoevenaars, Richard G. Hibbert,Andreas Lingnau, Ulf Forssmann,Janine Schuurman,Paul W.H.I. Parren,Rob N. de Jong,Esther C.W. Breij
openalex(2023)
crossref(2023)
Proceedings of the National Academy of Sciences of the United States of Americano. 50 (2023): e2310666120-e2310666120
加载更多
作者统计
#Papers: 479
#Citation: 31538
H-Index: 91
G-Index: 168
Sociability: 8
Diversity: 0
Activity: 1
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn